Quality upscaling, upscaling quality

Phytex is an Australian owned and operated manufacturer of high quality active pharmaceutical ingredients (APIs).
 
Since 1979, Phytex has been developing, scaling and commercialising APIs for the global healthcare and research industry.
 
Phytex is licensed with the Australian Therapeutic Goods Administration (TGA) as well as the U.S. Food and Drug Administration (FDA). The organisation has also been recognised as a silver donor by USP for providing various purified Scopolamine derivatives (Hydrobromide (1610001 – R10130) and Methscopolamine bromide (1421009 - R132F0)) and their impurities for USP Reference Standard qualification.
 
Working with Australian sourced raw materials, Phytex has long-term relationships with its suppliers ensuring customers continuity of supply.

The Phytex team comprises experts in Alkaloid extraction from natural sources with specialisation in Tropane, Indolizidine and Pyrrolizidine Alkaloids. Their focus is extraction (liquid/solid), isolation and purification of high quality, pharmacopeial compliant APIs as well as extracts and intermediates if required. The team is available to support partners through the entire drug development journey, from research and development, regulatory navigation to commercial scaling.
 
Phytex is a member of the Royal Australian Chemical Institute and a founding member of the Active Pharmaceutical Ingredient Manufacturers Association of Australia.
 
In 2016, Stuart Smith succeeded Reginald as Managing Director after more than a decade of mentorship. Under Stuart’s leadership, Phytex continues to go from strength to strength expanding the manufacturing capabilities and technical team to continue to provide customers with the highest quality products and services.

For more than 40 years of operations, Phytex is proud of its impeccable track record of zero product recalls.